- Home
- PBFS vs DCTH Comparison
PBFS vs DCTH Comparison
Compare PBFS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- DCTH
- Stock Information
- Founded
- PBFS 1889
- DCTH 1988
- Country
- PBFS United States
- DCTH United States
- Employees
- PBFS N/A
- DCTH N/A
- Industry
- PBFS Banks
- DCTH Medical/Dental Instruments
- Sector
- PBFS Finance
- DCTH Health Care
- Exchange
- PBFS Nasdaq
- DCTH Nasdaq
- Market Cap
- PBFS 329.3M
- DCTH 388.3M
- IPO Year
- PBFS N/A
- DCTH N/A
- Fundamental
- Price
- PBFS $13.02
- DCTH $12.04
- Analyst Decision
- PBFS
- DCTH Strong Buy
- Analyst Count
- PBFS 0
- DCTH 4
- Target Price
- PBFS N/A
- DCTH $24.50
- AVG Volume (30 Days)
- PBFS 27.7K
- DCTH 727.1K
- Earning Date
- PBFS 11-11-2025
- DCTH 11-07-2025
- Dividend Yield
- PBFS N/A
- DCTH N/A
- EPS Growth
- PBFS 50.26
- DCTH N/A
- EPS
- PBFS 0.91
- DCTH 0.06
- Revenue
- PBFS $91,369,000.00
- DCTH $70,240,000.00
- Revenue This Year
- PBFS N/A
- DCTH $159.22
- Revenue Next Year
- PBFS N/A
- DCTH $42.78
- P/E Ratio
- PBFS $14.43
- DCTH $202.24
- Revenue Growth
- PBFS 23.15
- DCTH 491.35
- 52 Week Low
- PBFS $10.60
- DCTH $8.77
- 52 Week High
- PBFS $13.65
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- PBFS 49.03
- DCTH 62.80
- Support Level
- PBFS $12.72
- DCTH $11.25
- Resistance Level
- PBFS $13.19
- DCTH $12.05
- Average True Range (ATR)
- PBFS 0.16
- DCTH 0.53
- MACD
- PBFS -0.03
- DCTH 0.11
- Stochastic Oscillator
- PBFS 52.63
- DCTH 97.28
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.